A new study led by La Jolla Institute for Immunology scientists found that children who experience multiple dengue virus infections develop protective T cells, which help fight the virus. These T cells appear to be key to dengue virus immunity and may inform the development of a vaccine that prompts a similar response.
The collaboration aims to accelerate antibody discovery and development using Harbour BioMed's technology platform and Insilico's AI expertise. The companies will develop next-generation AI-powered antibodies for immunology, oncology, and neuroscience, aiming to deliver innovative therapies with enhanced specificity, efficacy, and safety.
Researchers at La Jolla Institute for Immunology have discovered a human antibody called mAb 3A6 that may prove useful against deadly outbreaks. The antibody was isolated from an Ebola survivor and found to block infection by binding to the viral stalk, offering protection at a very low dose.
Researchers have developed two therapeutic cocktails that inhibit key molecules, stopping immune cells from overreacting to allergens. The treatments reduced asthma attacks in mice by erasing the immune system's memory of asthma-causing allergens.
Three early-career scientists, Dr. Omar Abudayyeh, Dr. Caleb Lareau, and Dr. Yuzhong Liu, are awarded $150,000 grants for their innovative research on human immunology, vaccine discovery, and cancer immunotherapy. Their proposals aim to advance our understanding of the immune system and develop new treatments for deadly diseases.
A study published in The Journal of Immunology found that supplementing maternal diet with vitamin E during pregnancy can reduce the development of food allergy and anaphylaxis in newborn mice. This potential breakthrough could help address the alarming increase in peanut allergy among children.
Researchers have discovered double negative memory B cells, a novel subset of immune cells that are more dysfunctional when in close contact with tumors. These cells may be a useful diagnostic marker and a potential target for developing new immunotherapies.
Researchers propose systems immunology to tackle sepsis, identifying early warning signs and potential subtypes, which can lead to improved diagnostics and treatment. Targeted funding is urgently needed to develop large-scale omics studies and translate these insights into clinical results.
Researchers at La Jolla Institute for Immunology discovered that tissue-resident memory CD8 T cells rise up to fight infections in the small intestine, using spatial transcriptomics technology. These immune cells are split between villi and crypts, with progenitor-like cells replenishing effector T cells.
The International Alliance for Primary Immunodeficiency Societies has partnered with Rockefeller University Press to launch the Journal of Human Immunity, an open-access journal focused on human immunity and inborn errors of immunity. The journal aims to provide a platform for groundbreaking research and attract top-tier submissions.
A three-drug cocktail of drugs has been identified as a potential booster of CAR-T cancer therapy by researchers at the University of North Carolina. The cocktail preserves a critical cell subset called T-memory stem cells, which are crucial for long-term persistence of CAR-T cells.
Stephania Cormier and colleagues lead a Frontiers in Immunology research collaboration to explain RSV's complex interplay with host immune responses. The team identifies gaps in knowledge, hindering therapeutics and vaccines development.
A new study by La Jolla Institute for Immunology researchers suggests that many people may already have immune cells on standby to combat the H5N1 virus. The study found similarities between H5N1 and seasonal influenza viruses, allowing scientists to predict cross-reactive T cell responses that could help decrease disease severity.
A University of Toronto study discovered a new communication pathway between the gut and lung, highlighting the role of a little-known protozoan in shaping immune responses. The study found that this microbe can worsen airway inflammation in allergic asthma but provide protection against respiratory infections.
A team of researchers from Mass General Brigham has identified changes in immune cells that can predict patient recovery after cardiac arrest. The study suggests that a particular population of cells may provide protection against brain injury and a drug that can activate these cells, improving neurological outcomes in preclinical stud...
A prestigious professorship in immunology has been established at the Walter and Eliza Hall Institute, continuing Sir Gustav Nossal's groundbreaking work on immune tolerance. The position aims to nurture new generations of researchers and advance understanding of immune diseases such as lupus and rheumatoid arthritis.
Researchers at the University of Pittsburgh have discovered a molecular pathway involving protein BLIMP1 that generates Th2 cells in response to inhaled house dust mite, driving allergic asthma. The study also found signaling molecules IL2 and IL10 are required for BLIMP1 expression, offering new therapeutic options.
Researchers at the University of Pittsburgh found that blocking the uptake of lactic acid, a key factor in T cell exhaustion, can reinvigorate these cells. This new approach shows promise for improving tumor control and treatment outcomes in various cancers.
Two studies reveal that anaphylaxis management remains unclear, with only 14% of respondents confident in using epinephrine. EMS protocols also vary widely, with outdated definitions and inadequate recommendations for treatment.
A new study at an allergy clinic in a diverse community found that self-identified non-White patients were less likely to show vaccine hesitancy than the White patient group. Ethnicities included in the study showed Black, Hispanic and Asian ethnicities with lower rates of refusal compared to Whites.
Researchers found Itaconate stimulates immune cells to produce anti-viral proteins called interferons by blocking an enzyme called SDH, offering a potential therapy for autoimmune and infectious diseases.
Researchers at La Jolla Institute for Immunology have developed six lines of humanized mice to study human cases of COVID-19, shedding light on SARS-CoV-2's movement through the body and varying symptoms. The models help understand how different genetic backgrounds influence disease progression.
Researchers at La Jolla Institute for Immunology have captured the first detailed images of the Ebola virus nucleocapsid structure, which is crucial for replicating in host cells. This breakthrough may accelerate the development of universal antivirals that target this viral structure to combat multiple filoviruses.
Jakob Zimmermann is receiving a total of 1.6 million euros from the European Research Council (ERC) to study T-cell immune memory in the intestine and its connection with intestinal flora, aiming to develop new treatments for chronic inflammatory bowel diseases and vaccines.
Heidelberg researchers describe a new bottom-up approach to engineer precise immune responses using nanotechnology and synthetic biology. This innovative field holds promise for groundbreaking approaches in disease treatment and prevention.
Researchers at La Jolla Institute for Immunology have discovered immune cells, such as tissue resident memory cells, in the upper airway that can fight infections and build long-term immunity. These findings may lead to better vaccines and a deeper understanding of immunity against respiratory pathogens.
Scientists at Trinity College Dublin have identified a key biological pathway, the JAK/STAT pathway, that RSV suppresses and prevents immune system igniters from activating. This discovery provides a promising new target for therapeutic immune restoration and could lead to significant impact in treating RSV infections.
Pamela J. Bjorkman, K. Christopher Garcia, and Ian A. Wilson receive inaugural prize for their groundbreaking research in structural immunology, which has paved the way for novel disease treatments and revealed new insights into the immune system.
Researchers have developed a humanized mouse model with a fully functional human immune system, enabling the study of immunotherapy development, disease modeling, and vaccine development. The new model, called TruHuX, mounts specific antibody responses and can develop full-fledged systemic lupus autoimmunity.
The American College of Allergy, Asthma & Immunology (ACAAI) has issued a position paper on the safety of administering live vaccines to patients treated with dupilumab. The review suggests that treatment should not be stopped, but rather, shared decision-making between doctors and patients is recommended to weigh risks and benefits.
Researchers at La Jolla Institute for Immunology developed a computational method to link gene activity to molecular marks on DNA, potentially aiding in the detection of solid tumors and more accurate cancer diagnoses. This new approach utilizes machine learning tools to identify connections between genes and enhancers in the genome.
Researchers at St. Jude Children's Research Hospital found that a 'Goldilocks' binding strength between T-cell receptors and cancer proteins determines anti-cancer T-cell efficacy. The optimal middle-ground binding strength creates cancer-killing effector cells, while too little or too much stimulation leads to exhaustion.
Researchers at La Jolla Institute for Immunology found that people who experienced breakthrough COVID-19 infections develop T cells better equipped to recognize and target SARS-CoV-2. The study also discovered that B cells produce more diverse antibodies targeting common epitopes between the vaccine and variants.
Researchers at La Jolla Institute for Immunology have developed a new, rapid method to study phosphorylation and other post-translational modifications in immune cells. This method sheds light on signaling pathways that trigger T cell activation and reveals how phosphate groups direct specific gene expression responses.
Researchers at Tulane University identified a promising new approach to treating persistent neurological symptoms associated with Lyme disease. Fibroblast growth factor receptor inhibitors showed promise in reducing inflammation and cell death in brain and nerve tissue samples infected with Borrelia burgdorferi.
Researchers have developed a novel immunotheraphy targeting macrophages to induce tolerance in type 1 diabetes, demonstrating its potential as a curative treatment. The therapy also shows promise for other autoimmune diseases, with results suggesting no impact on the immune system's ability to capture and process liposomes.
Scientists from the La Jolla Institute for Immunology found that patients with 'cold' tumors produce cancer-fighting T cells, suggesting a potential cure from within. The researchers developed an approach called 'Identify, Predict, Validate' to detect these T cells in over 130 patients.
Researchers at McGill University Health Centre discovered that a century-old BCG vaccine can provide cross-protection against influenza A virus and COVID-19 by inducing trained immunity. The study's findings have significant implications for developing vaccines against emerging respiratory viruses.
Researchers at La Jolla Institute for Immunology have identified 137 unique T cell epitopes targeted by the immune system in patients with active TB. These findings may lead to the development of new diagnostics and therapies for the disease, which affects over 1.3 million people worldwide.
The new guidelines offer evidence-based recommendations for diagnosing and managing anaphylaxis and atopic dermatitis in pediatric and adult patients. The guidelines emphasize the importance of patient values and preferences in arriving at optimal recommendations, reflecting advancements in diversity, equity, and inclusion.
A recent study published in Annals of Allergy, Asthma and Immunology examines the effects of climate change on various allergic conditions, including atopic dermatitis, asthma, and seasonal allergies. The research suggests that environmental warming can lead to longer-lasting pollen seasons and increased T2 inflammation.
Researchers at La Jolla Institute for Immunology found that most T cells can still target epitopes on the new Pirola variant, suggesting people may be able to mount a response against it. The study's findings provide positive news in the fight against SARS-CoV-2, emphasizing the importance of vaccination with updated vaccines.
Researchers identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer. Combining immunotherapy with dupilumab boosted patients' immune systems and showed significant tumor reduction in six out of six cases.
Researchers at La Jolla Institute for Immunology and Massachusetts General Hospital mapped the genome to understand how IKAROS controls healthy B cell development. They found that IKAROS solves a big problem in B cell development by bringing together far-away genes through looping, leading to proper expression and antibody production.
The Snow Centre for Immune Health will transform how we understand and treat immune diseases, offering a whole-of-system approach to address debilitating conditions like lupus and rheumatoid arthritis. The centre aims to deliver transformational real and measurable impacts for patients through translational research.
The Icahn School of Medicine at Mount Sinai has been awarded a $5 million NIH grant to establish a state-of-the-art center dedicated to discovering and developing novel therapeutic targets for cancer therapy. The Center will utilize cutting-edge technologies and interdisciplinary collaborations to accelerate the translation of scientif...
Researchers led by Dr. Ming Li at Memorial Sloan Kettering Cancer Center investigate the molecular mechanisms of immune regulation and its role in cancer. They aim to uncover new biological insights to target the immune system for cancer therapy, building on recent advancements in immunotherapy.
Dr. Gailen Marshall was installed as president of the American College of Allergy, Asthma and Immunology (ACAAI), succeeding Dr. James Tracy who was elected as president-elect. Dr. Marshall is a renowned allergist and immunologist with extensive experience in clinical practice, research, and academia.
Scientists at the La Jolla Institute for Immunology have uncovered a group of T cells known as mucosal-associated invariant T (MAIT) cells. These cells can recognize the same markers whether they come from humans or mice, opening up new possibilities for treating infectious diseases and improving cancer immunotherapies. The study also ...
Researchers using cancer as a model system are uncovering basic principles of immune cell communication and spatial dynamics. Understanding these principles can lead to new treatments for various diseases, including viral infections and cancer.
New studies presented at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting highlight the dangers of excess mold on individuals with asthma. Effective methods for getting rid of mold and airborne allergens include HEPA filters, activated carbon filters, and UV-based technology.
A panel of experts has defined clinical remission in asthma treatment, requiring six criteria met over 12 months. The definition aims to set an aspirational goal for prolonged control and optimize medication adherence.
Researchers at St. Jude Children's Research Hospital discovered a subset of immune cells that slows Alzheimer's disease progression by interacting with microglia. The cells, called CD8+ T cells, use a molecular handshake to signal to the microglia to stop causing uncontrolled inflammation, which in turn slows plaque growth and symptoms.
Researchers at the Babraham Institute have discovered that the 3D organisation of DNA in B cells allows for genes far away from each other to come together during antibody generation. This finding has implications for understanding why antibody diversity declines with age and suggests potential interventions.
Researchers at La Jolla Institute for Immunology and Augusta University have identified a link between
Researchers at La Jolla Institute for Immunology have discovered the inner workings of Ebola virus replication inside host cells, revealing 'viral factories' that form clusters of viral proteins and genomes. These microscopic structures are formed in host cells and play a crucial role in the virus's life cycle.
Researchers have developed a computational tool to compare large datasets and predict immune responses to disease, potentially leading to better vaccines. The new algorithm, designed by La Jolla Institute for Immunology scientists, uses machine learning to identify underlying patterns in immune system data.
The IBS-KAI Conference will focus on viral diseases and immunology, featuring over 20 international experts. The conference aims to prepare for responses to future infectious diseases, including those with pandemic potentials.
Researchers found that blocking histamine-releasing factor (HRF) and immunoglobulin E (IgE) interactions may provide relief for patients with severe asthma. The study, published in The Journal of Allergy and Clinical Immunology, suggests two potential therapies, including HRF-2CA and a therapeutic antibody called SPF7-1.
Researchers from St. Jude Children's Research Hospital discovered NLRP12 to be the key molecule responsible for inducing inflammatory cell death and pathology in response to heme combined with other cellular damage or infection. This finding provides a new potential drug target to prevent morbidity in certain illnesses.